Literature DB >> 10832829

Association of nonsense mutation of dystrophin gene with disruption of sarcoglycan complex in X-linked dilated cardiomyopathy.

W M Franz1, M Müller, O J Müller, R Herrmann, T Rothmann, M Cremer, R D Cohn, T Voit, H A Katus.   

Abstract

BACKGROUND: In a systematic analysis of inherited forms of cardiomyopathy, we previously identified a family with X-linked dilated cardiomyopathy characterised by a mutation in the rod region of dystrophin. We have now attempted to eludicate the genetic mechanism involved in this disease, as well as the role of dystrophin-associated glycoproteins.
METHODS: The affected dystrophin epitope, which lacks binding to the dys-1 antibody, was analysed by single-strand conformation polymorphism analysis, reverse-transcription PCR, and DNA sequencing. Effects on dystrophin-associated glycoproteins were studied by immunohistochemistry and western blotting.
FINDINGS: A translation-termination mutation (C4148T) in exon 29 of the dystrophin gene was found in all affected family members. Alternative splicing rescued the reading frame and led to the expression of a dystrophin molecule lacking 50 aminoacids both in cardiac and skeletal muscle. Immunohistochemical analysis of the dystrophin-associated proteins revealed a reduction of beta-sarcoglycan and delta-sarcoglycan in the sarcolemma of cardiac muscle but not skeletal muscle tissue. However, western blotting revealed similar amounts of sarcoglycan subunits in both tissues.
INTERPRETATION: The molecular mechanism of this subtype of X-linked cardiomyopathy may be explained by a conformational change in exon-29-deleted dystrophin, resulting in disruption of the sarcoglycan assembly in heart muscle but not skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10832829     DOI: 10.1016/S0140-6736(00)02266-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  9 in total

Review 1.  Myofibrillar remodeling in cardiac hypertrophy, heart failure and cardiomyopathies.

Authors:  Jarmila Machackova; Judit Barta; Naranjan S Dhalla
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

2.  Genetic Counseling and Screening Issues in Familial Dilated Cardiomyopathy.

Authors:  E L Hanson; R E Hershberger
Journal:  J Genet Couns       Date:  2001-10       Impact factor: 2.537

Review 3.  Genetic causes of human heart failure.

Authors:  Hiroyuki Morita; Jonathan Seidman; Christine E Seidman
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 4.  A Comprehensive Outlook on Dilated Cardiomyopathy (DCM): State-Of-The-Art Developments with Special Emphasis on OMICS-Based Approaches.

Authors:  Vivek Sarohi; Shriya Srivastava; Trayambak Basak
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-01

Review 5.  Multiple pathogenetic mechanisms in X linked dilated cardiomyopathy.

Authors:  N Cohen; F Muntoni
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

6.  Dysferlin-mediated membrane repair protects the heart from stress-induced left ventricular injury.

Authors:  Renzhi Han; Dimple Bansal; Katsuya Miyake; Viviane P Muniz; Robert M Weiss; Paul L McNeil; Kevin P Campbell
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

Review 7.  X-Linked Dilated Cardiomyopathy: A Cardiospecific Phenotype of Dystrophinopathy.

Authors:  Akinori Nakamura
Journal:  Pharmaceuticals (Basel)       Date:  2015-06-09

Review 8.  Dystrophic Cardiomyopathy: Complex Pathobiological Processes to Generate Clinical Phenotype.

Authors:  Takeshi Tsuda; Kristi K Fitzgerald
Journal:  J Cardiovasc Dev Dis       Date:  2017-09-08

9.  Dystrophin Exon 29 Nonsense Mutations Cause a Variably Mild Phenotype.

Authors:  Rebecca S Moore; Sandya Tirupathi; Brian Herron; Andrew Sands; Patrick J Morrison
Journal:  Ulster Med J       Date:  2017-09-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.